This study found that the incidence of spondylolysis in a group of children with OI was much higher than in the normal pediatric population, which has been reported to be 2.6% to 4.0%. This incidence was also found to be higher than previously reported incidence of spondylolysis in OI patients (5.3%). The incidence of spondylolisthesis was also found to be much higher than that of the normal pediatric population (4.2%). It is important to recognize this higher incidence of these abnormalities and to anticipate future associated symptoms and potential worsening listhesis that can clinically affect the lifestyles of these children and potentially require surgical treatment. The clinical significance of these findings will necessitate long-term follow-up.
Background:
Atrial myxomas are the most common primary cardiac neoplasm. The majority (75%–80%) are located in the left atrium at the base of the foramen ovalis. Surgical removal can prevent dangerous obstructive or thromboembolic sequelae.
Hypothesis:
Atypically located tumors may present technical challenges requiring case‐specific surgical adaptations when visualization or surrounding cardiac structures are compromised.
Methods:
We describe 3 cases of atypically located atrial myxomas that required preoperative transesophageal echocardiography and computed tomography to afford the optimal surgical approach.
Conclusions:
These cases highlight the potential need for multimodality imaging of atypically located atrial myxomas to determine the optimal technical approach for excision. Clin. Cardiol. 2012 doi: 10.1002/clc.22027
The authors have no funding, financial relationships, or conflicts of interest to disclose.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.